Previous 10 | Next 10 |
home / stock / esaly / esaly news
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 TOKYO, July 21, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the inve...
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixi...
travellinglight/iStock via Getty Images In the company’s earnings call today, UnitedHealth ([[UNH]] +1.3%) said it needed more clarity before determining the coverage policy for Aduhelm, the Alzheimer’s drug developed by Biogen ([[BIIB]] -6.7%) and Eisai ([[ESALY]] -4....
Win McNamee/Getty Images News The acting commissioner of the Food and Drug Administration ((FDA)) Janet Woodcock admitted to possible lapses in the approval of Aduhelm (aducanumab), the Alzheimer’s’ therapy developed by Biogen ([[BIIB]] -0.0%) and Eisai ([[ESALY]] +0.1%). In an ...
travellinglight/iStock via Getty Images News that the Food and Drug Administration has called for a probe into the approval of Biogen's (BIIB) Alzheimer's drug is "more noise and stress" for holders, but unlikely to have a "tangible" impact on the drug, according to Stifel. "And for the...
Bet_Noire/iStock via Getty Images Biogen ([[BIIB]] -2.9%) shares sank to a session low amid reports that the acting head of the Food and Drug Administration ((FDA)) has called for a far-reaching federal investigation into the controversial approval of Alzheimer’s disease drug developed...
Bet_Noire/iStock via Getty Images The debate continues over the controversial FDA approval granted for Aduhelm (aducanumab), the Alzheimer's disease treatment developed by Biogen (BIIB) and Eisai (ESALY). The FDA officials who greenlighted the therapy under the agency’s accel...
gerenme/iStock via Getty Images The advancements in treatments for Alzheimer’s disease have spurred gains among large-cap pharmaceutical companies in the first half of 2021. Eisai ([[ESALY]] -0.9%) and Eli Lilly ([[LLY]] +0.7%) are among the five leading gainers in the pharmaceutical s...
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin re...
Grandbrothers/iStock Editorial via Getty Images In a detailed expose, journalists at STAT have uncovered the methods Biogen (BIIB) used in gaining approval of Aduhelm (aducanumab) -- a drug that was once shelved in 2019 -- including an off-the-books meeting with a key FDA official. That offic...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...